SemBioSys Genetics Inc. is a biotechnology company that is using its proprietary oilbody/oleosin-based protein production technology to develop high-value proteins including protein-based pharmaceuticals, industrial reagents, food additives, and nutritional oils. The company's strategy is to partner with other companies to enable the commercialization of products that might not otherwise be commercially viable because of high production/manufacturing costs.

PropertyValue
dbpedia-owl:Organisation/keyPersonPosition
  • James Szarko, President and CEO
dbpedia-owl:Organisation/locationCity
dbpedia-owl:Organisation/locationCountry
dbpedia-owl:Organisation/numberOfEmployees
  • 45 (xsd:integer)
dbpedia-owl:Organisation/type
dbpedia-owl:keyPersonPosition
  • James Szarko, President and CEO
dbpedia-owl:locationCity
dbpedia-owl:locationCountry
dbpedia-owl:numberOfEmployees
  • 45 (xsd:integer)
dbpedia-owl:type
dbpprop:abstract
  • SemBioSys Genetics Inc. is a biotechnology company that is using its proprietary oilbody/oleosin-based protein production technology to develop high-value proteins including protein-based pharmaceuticals, industrial reagents, food additives, and nutritional oils. The company's strategy is to partner with other companies to enable the commercialization of products that might not otherwise be commercially viable because of high production/manufacturing costs. In 2007, SemBioSys formed a new subsidiary, Botaneco, dedicated to the commercialization of SemBioSys’ natural oilbody products for cosmetic, personal care and prescription topical dermatology products. Botaneco produces, markets and sells its products under the brand name Hydresia(TM). Currently, SemBioSys is using the safflower plant to develop efficient and low cost production of high-value pharmaceutical proteins – biosimilar insulin and ApoA-1 Milano. Insulin is used to maintain blood sugar levels in patients with type I and type II diabetes. In a phase I/II clinical trial, SemBioSys demonstrated that its safflower produced insulin (SBS-1000) is bioequivalent to Humulin(R) R, a commercially available insulin. The demand for insulin is expected to increase as the world’s population increases and more people are diagnosed with diabetes. Since the current methods of insulin production require vast investments in capital, goods and equipment, there is a compelling need for more efficient production methodologies of insulin and SemBioSys is ready to meet this demand. Apo AI(Milano) is a variant of Apo AI, the major lipoprotein associated with high density lipoportein (HDL) or good cholesterol. SemBioSys is developing Apo AI(Milano) to reduce and stabilize vascular plaques associated with Acute Coronary Syndrome (ACS) and stroke indications. A University of Calgary spin-off (1994), SemBioSys is a publicly held firm. Investors include Bay City Capital, the Business Development Bank of Canada, Dow AgroSciences (a Canadian subsidiary of The Dow Chemical Company), Royal Bank Ventures Inc. (now RBC Capital Partners), the University of Calgary, Ventures West Capital Ltd. , and Dr. Maurice Moloney.
dbpprop:hasPhotoCollection
dbpprop:homepage
dbpprop:industry
  • Biotechnology
dbpprop:keyPeople
  • James Szarko, President and CEO
dbpprop:locationCity
dbpprop:locationCountry
dbpprop:name
  • SemBioSys Genetics Inc.
dbpprop:numEmployees
  • 45 (xsd:integer)
dbpprop:reference
dbpprop:type
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • SemBioSys Genetics Inc. is a biotechnology company that is using its proprietary oilbody/oleosin-based protein production technology to develop high-value proteins including protein-based pharmaceuticals, industrial reagents, food additives, and nutritional oils. The company's strategy is to partner with other companies to enable the commercialization of products that might not otherwise be commercially viable because of high production/manufacturing costs.
rdfs:label
  • SemBioSys Genetics
owl:sameAs
skos:subject
foaf:homepage
foaf:name
  • SemBioSys Genetics Inc.
foaf:page
is dbpprop:redirect of
is owl:sameAs of